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ABSTRACT
Introduction: The Rehabilitation EnAblement in
CHronic Heart Failure (REACH-HF) trial is part of a
research programme designed to develop and evaluate
a health professional facilitated, home-based, self-help
rehabilitation intervention to improve self-care and
health-related quality of life in people with heart failure
and their caregivers. The trial will assess the clinical
effectiveness and cost-effectiveness of the REACH-HF
intervention in patients with systolic heart failure and
impact on the outcomes of their caregivers.
Methods and analysis: A parallel two group
randomised controlled trial with 1:1 individual
allocation to the REACH-HF intervention plus usual care
(intervention group) or usual care alone (control
group) in 216 patients with systolic heart failure
(ejection fraction <45%) and their caregivers. The
intervention comprises a self-help manual delivered by
specially trained facilitators over a 12-week period. The
primary outcome measure is patients’ disease-specific
health-related quality of life measured using the
Minnesota Living with Heart Failure questionnaire at
12 months’ follow-up. Secondary outcomes include
survival and heart failure related hospitalisation, blood
biomarkers, psychological well-being, exercise capacity,
physical activity, other measures of quality of life,
patient safety and the quality of life, psychological well-
being and perceived burden of caregivers at 4, 6 and
12 months’ follow-up. A process evaluation will assess
fidelity of intervention delivery and explore potential
mediators and moderators of changes in health-related
quality of life in intervention and control group
patients. Qualitative studies will describe patient and
caregiver experiences of the intervention. An economic
evaluation will estimate the cost-effectiveness of the
REACH-HF intervention plus usual care versus usual
care alone in patients with systolic heart failure.
Ethics and dissemination: The study is approved
by the North West—Lancaster Research Ethics
Committee (ref 14/NW/1351). Findings will be
disseminated via journals and presentations to
publicise the research to clinicians, commissioners and
service users.
Trial registration number: ISRCTN86234930;
Pre-results.
INTRODUCTION
Heart failure (HF) is a generally progressive
condition that is estimated to affect 900 000
people in UK1 and is associated with signiﬁ-
cant health expenditure, amounting to
around 1.0–3.2% of the total healthcare
expenditure in Western Europe, North
America and Latin America.2
People with HF experience a range of
symptoms including shortness of breath at
rest or on exertion, fatigue, ﬂuid retention,
impaired cognitive function and appetite dis-
turbance.3 4 HF is categorised as either HF
with reduced ejection fraction (also known
as systolic HF or left ventricular systolic dys-
function), or HF with preserved ejection frac-
tion (also known as diastolic HF). Systolic HF
is due to impaired left ventricular contrac-
tion, which results in a reduced ejection frac-
tion (usually <45%) and diastolic HF is due
to stiffness of the ventricle wall delaying
ﬁlling of the heart chamber.5
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Advances in pharmacological therapies and devices
(implantable cardioverter deﬁbrillators and biventricular
pacing) have been shown to improve physiological para-
meters and quality of life, reduce symptoms and
decrease mortality and readmission rates.5 However, HF
continues to have signiﬁcant negative impacts on the
quality of life of patients and their families or care-
givers,6 remains a common cause of hospitalisation, and
accounts for a substantial personal and economic
burden.
Cardiac rehabilitation (CR) is a process by which
patients with heart disease, in partnership with health
professionals, are encouraged and supported to achieve
and maintain optimal physical health.7 A recent
Cochrane systematic review including 33 randomised
trials in 4740 individuals with HF showed that participa-
tion in exercise-based CR was associated with a signiﬁ-
cant reduction in the risk of overall hospitalisation
(relative risk: 0.75; 0.62 to 0.92, p=0.005) and
HF-speciﬁc hospitalisation (relative risk: 0.61; 0.46 to
0.80, p=0.0004) and important improvements in patient
health-related quality of life.8 Based on such accumulat-
ing evidence, in 2010 the UK National Institute of
Health and Care Excellence (NICE) recommended
offering CR based on supervised group exercise for
patients with systolic and diastolic HF.1 Despite this rec-
ommendation, a survey in 2012 indicated that few UK
centres (16% of those surveyed) had a speciﬁc rehabili-
tation programme for those with HF.9 The UK uptake of
rehabilitation for people with HF therefore remains
poor.9 A recent European survey on exercise training in
HF concluded that ‘too many patients are still denied a
highly recommended therapy’.10 We believe two key
solutions to this poor provision and uptake are the
development of a home-based self-help CR manual
designed to meet the needs of those with HF and the
close involvement of their caregivers.
The Rehabilitation EnAblement in CHronic Heart
Failure (REACH-HF) research programme was designed
to develop and evaluate a health professional facilitated
home-based self-help manual rehabilitation intervention
to improve self-care and health-related quality of life
(HRQoL) in people with HF and their caregivers.
AIMS AND HYPOTHESIS
This trial aims to assess the clinical effectiveness and
cost-effectiveness of the addition of the REACH-HF
intervention to usual care in patients with systolic HF
and their caregivers. The primary hypothesis is that
REACH-HF plus usual care (as received by participants
in the ‘intervention group’) compared with usual care
alone (as received by participants in the ‘control
group’) can improve the disease speciﬁc HRQoL of
patients at 12 months’ follow-up (primary outcome).
Secondary objectives of the trial are:
▸ To compare secondary outcomes between patients in
the intervention and control group (comprising the
composite outcome of all-cause death or HF-related
hospital admission, brain natriuretic peptide levels,
exercise capacity, psychological well-being, level of
physical activity, generic health-related quality of life
and safety);
▸ To estimate the cost-effectiveness of the REACH-HF
intervention plus usual care versus usual care alone,
for patients with systolic HF;
▸ To explore the moderators and mediators of change
in disease-speciﬁc HRQoL of patients in intervention
and control groups;
▸ To assess the impact of, acceptability and satisfaction
of the REACH-HF intervention to patients and
caregivers;
▸ To compare psychological well-being, quality of life,
self-care activities, and burden, between caregivers in
the intervention and control groups;
▸ To check the ﬁdelity of delivery of the REACH-HF
intervention to patients and caregivers.
METHODS AND ANALYSIS
This protocol is reported in accord with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 guidance for protocols of clinical
trials.11
Design
The study is a multicentre parallel two group rando-
mised superiority trial with individual participant alloca-
tion to intervention group or control group with nested
process and health economic evaluations. Given the
complex nature of the intervention, it is not possible to
blind participants or those involved in the provision of
care. Researchers undertaking collection of outcome
data and the statistician undertaking the data analysis
will be blinded to treatment allocation in order to min-
imise potential bias. An illustration of the study ﬂow is
given in ﬁgure 1.
Setting
The study will be conducted in four investigator centres
in the UK: Birmingham (Sandwell and West Birmingham
Hospitals NHS Trust), Cornwall (Royal Cornwall Hospitals
NHS Trust), Gwent (NHS Wales) and York (York
Teaching Hospital NHS Foundation Trust). Participants
will be recruited at each of the four sites. To achieve
adequate participant enrolment to sample size, each site
can recruit through either primary or secondary care
pathways, with each site having the opportunity to imple-
ment secondary strategies depending on recruitment per-
formance which will be formally reviewed periodically by
the central trial management team. Follow-up procedures
will be conducted on NHS and non-NHS premises.
Conduct of the study at each centre will be led by a local
Principal Investigator supported by a research nurse(s)
who has received training in Good Clinical Practice and
in the requirements of the study protocol. Each
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participating site is responsible for the recruitment and
scheduled follow-up visits of participants.
Study population
The study population includes patients and caregivers.
Participating patients will be aged 18 years or older and
have a conﬁrmed diagnosis of systolic HF on echocardi-
ography or angiography (ie, left ventricular ejection frac-
tion <45% within the past 5 years). Patients who have
undertaken CR within 12 months prior to enrolment
will be excluded, as will patients contraindicated to exer-
cise testing or exercise training (adjudged according to
adapted European Society of Cardiology guidelines for
HF).12 The complete list of patient inclusion and exclu-
sion criteria is provided in box 1.
Participating caregivers will be aged 18 years or older
and provide unpaid support to patients who could other-
wise not manage without such support. Unpaid support
includes emotional support, prompting with taking med-
ications, observing for signs and symptoms of HF,
getting prescriptions, encouraging participation in social
events and physical activity, helping with household tasks
or providing physical care.
A patient may still participate if s/he does not have an
identiﬁed caregiver, or if the patient’s caregiver is not
willing to participate. Similarly patients who are unable
Figure 1 Illustration of study flow.
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or not willing to undertake the exercise capacity assess-
ment will not be excluded.
Participants are free to withdraw from the study at any
time, and this will be emphasised during the consent
process. If a participant chooses to withdraw they will be
asked to provide a reason and the reason for withdrawal
will be noted. Participants do not have to provide a
reason and this will be reiterated by the PI (or
authorised delegate) in the event of a withdrawal
request. Data collected on participants prior to with-
drawal will be retained for analysis.
Randomisation
Participants will be randomly allocated in a 1:1 ratio to
either intervention or control group arms.
Randomisation will be stratiﬁed by investigator site and
baseline pro-brain natriuretic peptide (NT pro-BNP)
levels (≤2000, >2000 pg/mL) using minimisation to
facilitate balance between the two treatment arms.
Randomisation numbers will be computer generated
and assigned in strict sequence. At the point of random-
isation, participants will be assigned the next randomisa-
tion number in the sequence. To maintain concealment
and minimise selection bias, randomisation will be per-
formed after the baseline visit by a member of Peninsula
Clinical Trials Unit (CTU), independent from investiga-
tor teams, using a secure, web-based randomisation
system.
Intervention
The REACH-HF intervention is grounded in the support
needs and priorities of people living with HF and the
services that provide care for them. A systematic, six-step
Intervention Mapping framework13 guided intervention
development, drawing on research evidence, national
and international guidelines and stakeholder consulta-
tions with patients, caregivers and health professionals
to identify ‘targets for change’. In line with Intervention
Mapping regulatory processes, underpinning target
behaviour patterns and evidence-based change techni-
ques were matched to each behaviour-change target.14 A
key element of the intervention development process
was an active Patient and Public Involvement group con-
sisting of six people with a range of experiences with HF
and three caregivers of people with HF. The intervention
development process is described in detail elsewhere (CJ
Box 1 Trial entry criteria
Inclusion criteria
▸ Provision of informed consent to participate.
▸ Adults (aged ≥18 years).
▸ Patients who have a confirmed diagnosis of systolic heart failure (HF) on echocardiography (ie, left ventricular ejection fraction <45%
within the past 5 years).
▸ Patients who have experienced no deterioration of HF symptoms in the past 2 weeks resulting in hospitalisation or alteration of HF
medication
Exclusion criteria
▸ Patients who have undertaken cardiac rehabilitation (CR) within the past 12 months
▸ Patients who have received an intracardiac defibrillator (ICD), Cardiac Resynchronisation therapy (CRT) or combined CRT/ICD device
implanted in the last 6 months.
▸ Patients who have any of the following contraindications to exercise testing or exercise training documented in their medical notes:
– Early phase after acute coronary syndrome (up to 2 days)
– Untreated life-threatening cardiac arrhythmias
– Acute HF (during the initial period of haemodynamic instability)
– Uncontrolled hypertension (systolic blood pressure >200 and/or diastolic blood pressure >100)
– Advanced atrioventricular block
– Acute myocarditis and pericarditis
– Symptomatic aortic stenosis
– Severe hypertrophic obstructive cardiomyopathy
– Acute systemic illness
– Intracardiac thrombus
– Progressive worsening of exercise tolerance or dyspnoea at rest over previous 3–5 days
– Significant ischaemia during low-intensity exercise (<2 Metabolic equivalents, <50 Watts)
– Uncontrolled diabetes (blood glucose >16 mmol/L or glycated hemoglobin >9% or equivalent unit)
– Recent embolism
– Thrombophlebitis
– New-onset atrial fibrillation/atrial flutter
▸ Patients who are in a long term care establishment or who are unwilling or unable to travel to research assessments or accommodate
home visits.
▸ Patients who are unable to understand the study information or unable to complete the outcome questionnaires.
▸ Patients judged to be unable to participate in the study for any other reason (eg, psychiatric disorder, diagnosis of dementia, life threa-
tening co-morbidity)
▸ Patients participating in concurrent interventional research which may over-burden the patient or confound data collection.
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Greaves, C Deighan, P Doherty, et al. Development of a
facilitated self-care and rehabilitation intervention for
people with HF and their care givers: Rehabilitation
Enablement in Chronic Heart Failure (REACH-HF).
Submitted for publication 2015).
The REACH-HF intervention is a comprehensive self-
care support programme comprising the ‘Heart Failure
Manual’ (HF Manual), with a choice of two exercise pro-
grammes for patients, a ‘Family and Friends Resource’
for caregivers, a ‘Progress Tracker’ tool and a training
course for intervention facilitators.
Participating patients and caregivers will work through
the self-help manual over a 12-week period with facilita-
tion by a specially trained intervention facilitator
(cardiac nurse or physiotherapist by background), who
will help to build the patient’s and caregiver’s under-
standing of how to manage HF. The manual includes
information and interactive elements covering a wide
range of topics relating to living with/adapting to living
with HF, and includes four core elements:
1. An exercise training programme, tailored according
to initial ﬁtness assessments, delivered as a walking
programme or a chair-based exercise DVD, or a com-
bination of the two (the patient’s choice);
2. Managing stress /breathlessness /anxiety;
3. HF symptommonitoring (and associated help-seeking);
4. Understanding and taking medications.
Patients will be encouraged to use the progress tracker
booklet, which is designed to collect the following infor-
mation over the period of the intervention: changes in
physical and mental state, intensity of exercise and self-
reported walking speed, and degree of completion of
self-monitoring sections for physical activity, enjoyable
activities, frequency of self-weighing (to monitor ﬂuid
build-up), and frequency of self-reported use of stress-
management techniques. The Family and Friends
resource, a manual for use by caregivers, includes advice
on providing support, becoming a caregiver, managing
caregiver’s own health and well-being and getting help.
As a pragmatic trial of a self-help intervention which is
reliant on the willing engagement of recipients, there
are no speciﬁc strategies to improve participants’ adher-
ence to intervention protocol. Intervention delivery may
be discontinued at any time at the request of a partici-
pant or by the intervention facilitator if they determine
that the intervention may be the cause of undue harm.
Adherence to intervention protocols from the per-
spective of the intervention facilitators will be ascer-
tained through ﬁdelity assessment described herein.
Usual care
In accord with ﬁndings of our national survey,9 patients
with HF typically do not receive CR, despite NICE
recommendations.1 The choice of a usual care (no
rehabilitation) comparator in the REACH-HF trial is
therefore reﬂective of the situation for the vast majority
of patients with HF. In this trial, intervention and
control group patients will receive usual medical
management for HF according to national and local
guidelines, including specialist HF nurse care. The use
of care services, including those provided by specialist
HF nurses in the community and in secondary care, will
be documented at each follow-up through participants’
completion of healthcare resource use questionnaires
and by collection of concomitant medication usage as
reported by participants.
Outcome measures
Outcome data will be collected at 4, 6 and 12 months
following the baseline visit (table 1—Tabulated summary
of study schedule). The 4-month time point coincides
with the end of the 3-month intervention delivery
period for participants in the intervention arm. This
allows a 1 month period after the baseline visit for com-
pletion of randomisation and referral processes.
Primary outcome
Patient disease-speciﬁc HRQoL measured using the
Minnesota Living with HF questionnaire (MLHFQ) at
12 months. The questionnaire consists of 21 items and is
designed to represent the ways HF and treatments can
affect the key physical, emotional, social and mental
dimensions of an individual’s quality of life.15
Secondary outcomes
Patients
▸ Composite outcome of death or hospital admission
related to HF or not related to HF. All instances of
hospitalisation and death will be recorded and made
accessible to an independent adjudication panel of
three experienced cardiologists who will ascertain
whether or not reported events are HF-related.
▸ NT pro-BNP levels. Natriuretic peptide levels are ele-
vated in patients with HF.16
▸ Exercise capacity (incremental shuttle walk test
(ISWT)).17
▸ Physical activity level (accelerometry over a 7-day
period, measured using the GENEActiv Original
accelerometer).18
▸ Psychological well-being using Hospital Anxiety and
Depression Scale questionnaire (HADS).19
▸ Generic HRQoL using the EQ-5D-5L questionnaire.20
▸ Disease-speciﬁc quality of life using the Health-
related Quality of Life (HeartQoL) questionnaire.21
▸ Self-care of HF Index questionnaire (SCHFI).22
▸ Healthcare utilisation (ie, primary and secondary
care contacts, social care contacts and relevant medi-
cation usage).
▸ Self-efﬁcacy for key behaviours questionnaires (devel-
oped by the research team).
▸ Safety; recording and reporting of serious adverse
events. Any adverse event or adverse reaction will be
regarded as serious if it: results in death, is life-
threatening, requires hospitalisation or prolongation of
existing hospitalisation, results in persistent or signiﬁ-
cant disability or incapacity. All serious adverse events
Taylor RS, et al. BMJ Open 2015;5:e009994. doi:10.1136/bmjopen-2015-009994 5
Open Access
copyright.
 o
n
 February 21, 2020 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-009994 on 23 December 2015. Downloaded from 
that occur during the trial will be recorded and
reported to the Ethics Committee, the Data Monitoring
Committee and the Trial Steering Committee.
Caregivers
▸ Psychological well-being using the HADS.19
▸ Generic HRQoL using the EQ-5D-5L questionnaire.20
▸ Caregiver Contribution to Self-care of HF Index ques-
tionnaire (CC-SCHFI).22
▸ Caregiver Burden Questionnaire—HF.23
▸ Family Caregiver Quality of Life Scale questionnaire
(FAMQOL).24
Sample size
The sample size is based on an effect size that repre-
sents a clinically important difference and is plausible.
The developers of the MLHFQ have determined that
ﬁve points is the minimal clinically important differ-
ence in score.15 With a type I error of 0.05 and power
of 90%, 85 patients per group are required to detect a
ﬁve-point difference in the MLHFQ score, assuming a
SD of 10.25 With an attrition rate of 20% (in accord-
ance with the level of attrition seen in previous
trials),26 27 108 patients are required per group. The
plausibility of this between group difference is sup-
ported by the Cochrane review of CR in HF, which
reported a mean pooled between group difference of
10.3 (95% CI 4.8 to 15.9) points in MLHFQ score.28
The proposed sample size is likely to be conservative
given the analysis of covariance approach to primary
outcome analysis and adequate to detect an important
difference in a number of secondary outcomes,
including the ISWT (50 m) and Hospital Anxiety and
Depression Scale (1.5 points) at a power of 80% or
higher.
Table 1 Tabulated summary of study schedule
Baseline Allocation Postallocation
Time point t0
+4 months
t1
+6 months*
t2
+12 months
t3
Enrolment
Eligibility screen X
Informed consent X
Demographics X
Medical history X
Allocation† X
Interventions
Intervention group
Usual care
HF manual facilitation‡
Control group
Usual care
Assessments
MLHFQ Questionnaire X X X X
SCHFI Questionnaire X X X X
HADS Questionnaire X X X X
Heart-QOL Questionnaire X X X X
EQ-5D-5L Questionnaire X X X X
Self-efficacy for key behaviours questionnaire X X
CC-SCHFI Questionnaire (caregivers) X X X X
CBQ-HF Questionnaire (caregivers) X X X X
FAMQOL Questionnaire (caregivers) X X X X
HADS Questionnaire (caregivers) X X X X
EQ-5D-5L Questionnaire (caregivers) X X X X
Resource use data collection X X X
Blood sample for pro-BnP levels X X
Incremental shuttle walk test X X X
Accelerometry X X X
Safety monitoring
Adverse event reporting
*Six month time point is conducted by post. Participants are not required to visit the research centre at this time point.
†Allocation will be performed by Peninsula Clinical Trials Unit (CTU), typically within 10 days of the baseline clinic, following receipt of
baseline data and blood sample result.
‡HF Manual facilitation will commence approximately 1 month post randomisation.
HADS, Hospital Anxiety and Depression Scale questionnaire; HF, heart failure; MLHFQ, Minnesota Living with HF questionnaire; pro-BNP,
pro-brain natriuretic peptide; QoL, quality of life; SCHFI, Self-care of HF Index questionnaire; CC-SCHFI, Caregiver Contribution to Self-care
of HF Index questionnaire; CBQ-HF, The Caregiver Burden Questionnaire for HF; FAMQOL, Family Caregiver QoL questionnaire.
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Trial data collection
Trial data are collected from participants during three
clinic visits (at baseline, 4 and 12 months) and by postal
questionnaire at 6 months. To encourage participant
retention and completeness of data, participants may
claim travel expenses associated with clinic visits and are
provided with postage-paid envelopes to return question-
naires by post. Furthermore, visits may be partially con-
ducted at participants’ homes if mutually convenient for
the research nurse and participant. Participants who are
unwilling or unable to travel to research assessments or
accommodate home visits are excluded at the point of
consent.
At the baseline clinic visit, after written informed
consent has been obtained by the research nurse, the
following information will be collected:
▸ Medical history (including comorbidities (number
and severity scored with Charlson Co-morbidity
Index), New York Heart Association class, HF aeti-
ology, concomitant HF medication and presence of
implantable HF devices);
▸ Healthcare resource utilisation over the prior
6 months;
▸ Sociodemographic information (ie, date of birth, eth-
nicity, height, weight, employment status, education
level, smoking status).
Participating patients will be asked to:
▸ Complete a booklet comprising the primary and sec-
ondary outcome questionnaires;
▸ Perform an the incremental shuttle walk test;
▸ Provide a (∼4 mL) blood sample for measurement of
NT pro-BNP levels;
▸ Wear a wrist-worn accelerometer for 7 days.
Participating caregivers will also be asked to provide
sociodemographic information (ie, date of birth, ethni-
city, weight, employment status, education level and
smoking status) and to complete a booklet comprising
their outcome questionnaires.
Patient and caregiver follow-up outcome assessments
will be performed at clinic visits held at 4 and
12 months after the baseline visit, with a postal
follow-up (questionnaire-based outcomes only) per-
formed at the 6-month time point. At the 4 and
12-month clinic visits investigators will record details
of any changes to participants’ HF medication or
implantable cardiac devices, details of any hospitalisa-
tions and healthcare resource utilisation since the pre-
vious visit. Investigators will also check that
participating patients have not become contraindi-
cated to exercise testing before conducting the incre-
mental shuttle walk test. Blood samples (collected at
baseline and 12 months only) will be dispatched to a
central laboratory (Royal Cornwall Hospital NHS
Trust) for determination of NT pro-BNP levels.
Accelerometer devices will be returned by participants
using postage-paid envelopes after 7 days of wearing.
The devices will be returned to the CTU for data
extraction. Participant safety will be monitored
through recording, reporting and review of all serious
adverse events collected from baseline until ﬁnal
follow-up visit.
Data collected at clinic visits will be recorded on study
speciﬁc case report forms (CRFs) by the research team
at each site. Completed CRFs will be checked and
signed at the research sites by a member of the research
team before being sent to the CTU. Original CRF pages
and completed questionnaire booklets will be posted to
the CTU at agreed time points for double-data entry in
to the study database. Accelerometer data will be
imported directly into the study database. All forms and
data will be tracked using a web-based trial management
system. Double-entered data will be compared for dis-
crepancies according to a data management plan held
in CTU. Discrepant data will be veriﬁed using the ori-
ginal paper data sheets.
Participant names and addresses will be collected for
the purpose of managing questionnaire dispatch, inter-
vention delivery and participant interviews. Investigators
will ensure that the participants’ anonymity is main-
tained on all other documents. Within the CTU, anon-
ymised and identiﬁable study data will be stored
separately, to prevent the identiﬁcation of participants
from research records, in locked ﬁling cabinets within a
locked ofﬁce. Electronic records will be stored by the
CTU in a web-based, SQL server database, housed on a
restricted access, secure server maintained by the
University of Plymouth. Data in the database will be
backed up daily. The website will be encrypted using
SSL. Data will be collected and stored in accordance
with the Data Protection Act 1998. Direct access to the
trial data will be restricted to members of the research
team and the CTU, with access granted to the Sponsor
on request. Access to the database will be overseen by
the CTU data manager and trial manager.
Process evaluation
The process evaluation seeks to assess intervention ﬁdel-
ity, patients’ and caregivers’ experiences of trial partici-
pation, and to explore processes that may be responsible
for change in the primary outcome of HRQoL (includ-
ing intermediate changes in secondary outcomes and
changes in self-care behaviour patterns of patients
receiving the REACH-HF intervention).29
Patient and caregivers’ views on the intervention will
also be explored as part of the process evaluation. Five dis-
tinct studies comprise the process evaluation as follows:
Process evaluation study 1: Intervention fidelity
A ﬁdelity checklist developed and piloted as part of the
REACH-HF programme (CJ Greaves, et al Submitted for
publication 2015) will be used to assess ﬁdelity of deliv-
ery of the intended intervention processes. This will be
achieved by analysing recordings of all contacts (tele-
phone and face to face) between intervention facilitators
and 20 purposively sampled patient participants.
Contacts will be audio recorded by intervention
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facilitators and the ﬁles made accessible to two research-
ers who were part of the REACH-HF intervention devel-
opment team (a chartered health psychologist and a
registered nurse (by background)) who will complete
the checklist while listening to the recordings. The
check list is based on the Dreyfus scale.30 This will clarify
how well (or otherwise) intervention components are
delivered and received and will also allow researchers to
describe variability in ﬁdelity of delivery across patients
and facilitators.
Process evaluation study 2: Experiences of patients
Interviews with each of 20 patients selected above will be
conducted immediately after completion of intervention
delivery and again at 12 months after the baseline visit.
The interviews will be audio recorded and transcribed
verbatim. Interviews will be conducted according to
topic guides covering patients’ engagement with the
intervention, their relationship with their facilitator,
involvement of family and friends, use of the manual,
behavioural change and psychological adjustments to
living with HF.
Process evaluation study 3: Experiences of caregivers
Interviews with up to 20 purposively sampled caregivers
(including caregivers of patients participating in Study
1) will be conducted at 4 and 12 months. Where pos-
sible, the patient and the caregiver will be interviewed
separately. Topics covered in the interviews will include
the caregiver’s role before participating in the
REACH-HF trial, their engagement with the interven-
tion, the impact of the intervention, the caregiver’s rela-
tionships with the patient and the facilitator and the
ways in which the caregiver has adjusted his/her behav-
iour as a result of the intervention. The researcher
leading the caregiver interviews will work closely with
the researcher conducting the patient interviews and
will review the topic guide throughout the study so that
questions are informed by relevant emerging topics.
Interviews will be audio recorded and transcribed
verbatim.
Process evaluation study 4: Identification of potential
outcomes as mediators of effectiveness
Observed differences in secondary outcomes at inter-
mediate follow-up points (4 and 6 months) provide an
indicator of change for participants in the intervention
and control groups. Such changes may be predictive of
the primary outcome of MLHFQ at 12 months. Potential
intermediate outcomes that may be considered include
exercise capacity, psychological well-being, physical activ-
ity and self-efﬁcacy for key behaviours including physical
activity.
Process evaluation study 5: Use of progress trackers to
identify patient changes associated with effectiveness
As described earlier, the REACH-HF Manual includes a
progress tracker which intervention patients will be
encouraged to use to track their progress including
physical activity, mood, symptoms and self-care actions.
At the end of the intervention delivery period, copies of
the participants’ progress trackers will be provided to
the research team and digitally scanned. This informa-
tion together with the number of facilitator contacts and
total contact time received, will allow characterisation of
individual patient engagement in the intervention. To
the extent that this is the case, tracker scores can be
used to explore potential changes which indicate likeli-
hood of intervention success.
Economic evaluation
An economic evaluation will be undertaken to estimate
the cost-effectiveness of the REACH-HF intervention
plus usual care versus usual care alone in patients with
systolic HF. Cost-effectiveness analyses will be undertaken
using clinical and resource-use data collected within the
trial over a 12-month time horizon. The primary per-
spective will be that of the UK NHS and Personal Social
Services, with a broader perspective, addressing partial
patient and societal perspective, considered in sensitivity
analyses. The primary economic end point will be the
quality-adjusted life-year (QALY), using the EQ-5D-5L,
over the 12-month follow-up. The economic evaluation
will estimate the incremental cost per QALY associated
with the REACH-HF intervention.
The additional (incremental) costs associated with
delivery of the HF Manual, when added to usual care,
will be estimated using resource use data collected
within-trial, and unit costs for resource use from national
published or NHS sources. Resource use is expected to
consist of time input from REACH-HF facilitators, super-
vision for facilitators, training costs for facilitators and
consumables (eg, booklets). Data on facilitator time
input will be captured via facilitator self-report within
trial at participant level, using purpose-designed forms.
Health, social care and other resource use data will be
collected within trial at participant level and are collect-
ively regarded as a secondary outcome measure.
Resource use data will be used in combination with unit
costs to compare health, social care and other resource
use between groups, as perspective employed. Data will
be collected from participants by self-reported (inter-
viewer administered) participant questionnaire at base-
line, 4-month and 12-month time points. Hospitalisation
data (events) will be collected as part of ‘adverse event’
reporting and HF related medication data as reported
by patients will be captured by the research nurse at the
research clinics.
Data analysis
Primary and secondary outcomes
All analyses, quantitative and qualitative, will be con-
ducted according to best practise and reported in
accordance with Consolidated Standards of Reporting
Trials (CONSORT) guidelines for reporting of clinical
trials31 and appropriate guidelines for reporting process
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evaluations32 and qualitative research.33 Baseline socio-
demographic and health-related variables will be
reported descriptively by treatment arm, in order to
assess whether the inferential analyses require adjust-
ment for any unbalanced variables.
The primary analyses for all patient and caregiver out-
comes will be based on a between-group, intention-to-
treat, complete case approach, using data collected at
12 months’ follow-up. The outcomes will be analysed
using the regression method appropriate to the data,
that is, linear regression modelling for continuous out-
comes, survival analysis based on the Cox proportional
hazards regression model for time-to-event data, and
Tobit regression analysis for EQ-5D-5L. All analyses will
adjust for baseline score of the outcome variable (where
applicable), as well as minimisation variables previously
described, and sociodemographic and health-related
variables that are found to be unbalanced at baseline.
Secondary analyses will be undertaken on patient and
caregiver outcomes as repeated measures analysis using
all follow-up assessment points (4, 6 and 12 months). In
addition, a per protocol analysis of the primary outcome
will be performed using 12-month follow-up data. A per
protocol deﬁnition (based on a minimum level of inter-
vention uptake and adherence deemed necessary to
achieve improvement in outcomes) will be agreed prior
to the start of data analysis. If there is more than 5% loss
to follow-up for the primary outcome at 12 months, mul-
tiple imputation methods will be used as a sensitivity
analysis to address the issue of missing data. The follow-
ing subgroups will be assessed: the stratiﬁcation variables
of trial centre and severity of HF (NT pro-BNP levels),
plus time since HF diagnosis and the inclusion (or not)
of a caregiver.
The potential for differential intervention effects
within patient subgroups (ie, moderation by patient
characteristics) will be explored using interactions within
linear regression modelling for the primary outcome
only. Mediation analyses will be used to assess the extent
to which secondary outcomes at intermediate follow-up
(eg, self-efﬁcacy or physical activity levels at 4 months)
or progress tracker self-care behaviours (eg, self-reported
exercise, stress or anxiety management activities) can
explain between-group differences in the primary
outcome at 12 months. Moderation and mediation ana-
lyses will be exploratory in nature as no formal power
calculation for interaction effects has been performed.
Serious adverse events will be presented descriptively
by treatment arm.
All between group outcome results will be presented
as means and 95% CIs. No correction of p values for
multiplicity of testing will be undertaken. However, the
primary outcome (MLHFQ at 12 months) analysis will
be performed before all other analyses and the p values
of all subsequent analyses interpreted in the context of
multiple testing. No interim analyses will be performed.
All analyses will be conducted by a statistician who is
blinded to treatment arm, using Stata V.12.
Economic outcomes
Means (and SDs) for resource use and costs will be pre-
sented for baseline assessment, and for resource use
over the 12-month follow-up period. Regression
methods will be used to estimate mean costs per group
and to compare mean costs between treatment and
control groups. MLHFQ data will be drawn from the
main statistical analyses. QALY data will be derived from
trial data on EQ-5D-5L, using a UK algorithm/tariff, in
the ﬁrst instance those derived from Dolan34 (via van-
Hout et al35; although it is expected that a UK tariff will
be published at the time of analysis), for the 5-level EQ-
5D). Derived health state values will be used to estimate
QALYs through application of standard area-under-
-the-curve methods36 using all data from baseline to
12-month. Analysis of mean QALY per group, and differ-
ences between groups will be undertaken using regres-
sion based methods, adjusting for baseline EQ-5D-5L,
and using covariates as the main statistical analyses on
effectiveness. As analyses are over a 12-month period no
discounting of (future) costs or outcomes is required.
Qualitative outcomes
A thematic analysis of interviews will be conducted37 38
to generate emerging themes and overarching themes.37
Other members of the team will conduct independent
analyses of subsets of the data, and the qualitative team
will meet regularly to discuss coding and analysis.
Reﬂexive notes will also be used to help assure transpar-
ency and trustworthiness of the analysis.39 The analysis
will characterise patients’ observed and self-reported
responses to the intervention and link these responses
to overall use and perceived beneﬁt, identifying interper-
sonal and intrapersonal processes that shape effective-
ness or ineffectiveness of the intervention. At 4 months,
patients’ engagement with, response to and use of the
REACH-HF Manual will be characterised and differences
between patients noted. At 12 months overall use of and
beneﬁt derived from the REACH-HF manual, and main-
tenance of self-care behaviours and coping skills will be
characterised and linked to individual differences in
4-month responses. This will allow a qualitative descrip-
tion of potential pathways and barriers to improvement.
Data from the caregiver interviews will be analysed using
similar methods.
Data monitoring and quality assurance
The Site Principal Investigators ( JA, HD, PD, RD, KJ,
RVL) or authorised delegate will check completed CRFs
for missing data or obvious errors before the forms are
sent to the CTU. Data will be monitored centrally for
quality and completeness by the CTU and every effort
will be made to recover data from incomplete forms
where possible. The CTU data manager will oversee data
tracking and data entry and initiate processes to resolve
data queries where necessary. The CTU trial managers
(CH and VE) will devise a monitoring plan speciﬁc to
the study which will include central monitoring
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strategies and study site visits as appropriate.
Participating sites will be required to permit the CTU
trial manager or deputy, or representative of the
sponsor, to undertake study-related monitoring to
ensure compliance with the approved study protocol
and applicable standard operating procedures (SOPs),
providing direct access to source data and documents as
requested. All study procedures will be conducted in
compliance with the protocol and according to the prin-
ciples of the International Conference on
Harmonisation Good Clinical Practice (ICH GCP).
Procedures speciﬁcally conducted by the CTU team (eg,
data management, study management and study moni-
toring) will be conducted in compliance with CTU
SOPs.
Trial management and independent committees
Team members directly involved with the day-to-day
running of the trial will meet weekly to discuss trial pro-
gress, teleconferencing with site PIs on a monthly basis
with email and telephone exchange as necessary
between. The Programme Management Group includ-
ing health economics, statistics, process evaluation and
patient and public representation will meet on a termly
basis to review status of the overall programme, includ-
ing trial progress.
The REACH-HF Programme Steering Committee
(Chair: Professor Martin Cowie and four other inde-
pendent members including a patient and public
involvement representative) have formally agreed to
adopt the role of Trial Steering Committee and will
oversee the conduct of the trial with safety and ethics
review by a fully independent Data Monitoring
Committee (Chair: Dr Ann-Dorthe Zwisler and two
other independent members). Evidence for treatment
differences in the main efﬁcacy outcome measures will
not be monitored through review of accumulating
outcome data and no interim data analyses will be
conducted.
The Trial Steering Committee and Data Monitoring
Committee meet one to two times per year. Detailed
descriptions of the remit and function of the oversight
committees are documented in speciﬁc charters held in
the Trial Master File by CTU.
ETHICS AND DISSEMINATION
The study will be conducted in accordance with the
ethical principles that have their origin in the
Declaration of Helsinki and that are consistent with ICH
GCP, and in accordance with the Research Governance
Framework for Health and Social Care, Second edition
(2005). The study is sponsored by Royal Cornwall
Hospitals NHS Trust (Research, Development &
Innovation Department, Royal Cornwall Hospital,
Treliske, Truro, Cornwall, TR1 3LJ). Written informed
consent will be obtained from all participants prior to
study enrolment. Participants enrolled into the study are
covered by indemnity for negligent harm arising from
the management, design and conduct of the research
through standard NHS Indemnity arrangements. The
study is approved by the National Research Ethics
Service Committee North West—Lancaster Research
Ethics Committee (reference 14/NW/1351). Any subse-
quent amendments will be made using the Integrated
Research Applications System in order to maintain
ethical approval and NHS permissions. Amended docu-
ments will be provided to investigator sites by CTU. In
the event of changes to study design requiring signiﬁ-
cant amendment to the content of the participant infor-
mation sheet, participants will be required to provide
renewed informed consent.
Findings will be published in peer-reviewed journals
and presented at local, national and international meet-
ings and conferences to publicise and explain the
research to clinicians, commissioners and service users. A
ﬁnal report will be submitted to the National Institute for
Health Research and a summary report will be circulated
to NHS commissioners and service providers, patient
groups and trial participants. All investigators will have
access to the ﬁnal data set. Participant-level data sets will
be made accessible on a controlled access basis.
CONCLUSION
This randomised controlled trial aims to assess the clin-
ical and cost-effectiveness of the Rehabilitation
Enablement in Chronic Heart Failure (REACH-HF)
intervention, a manualised home-based rehabilitation
intervention designed to improve self-care and HRQoL
in people with systolic HF. We will also assess the out-
comes of caregivers. The study results will provide valu-
able information for clinicians, policymakers, patients
and their caregivers about the role of self-directed
rehabilitation interventions and has the potential to
positively impact on the current dearth in the provision
and uptake of rehabilitation services for people with HF
and caregiver support.
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